Systemic anti-cancer therapy for advanced non-small-cell lung cancer: treatment options

Squamous pathways

<table>
<thead>
<tr>
<th>RET fusion positive</th>
<th>NTRK fusion positive</th>
<th>KRAS G12C positive</th>
<th>METex14 skipping alteration</th>
<th>EGFRex20 insertion positive</th>
<th>BRAF V600 positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD-L1 &lt;50%</td>
<td>PD-L1 &lt;50%</td>
<td>PD-L1 &lt;50%</td>
<td>PD-L1 &lt;50%</td>
<td>PD-L1 &lt;50%</td>
<td>PD-L1 &lt;50%</td>
</tr>
<tr>
<td>No targetable mutations</td>
<td>No targetable mutations</td>
<td>No targetable mutations</td>
<td>No targetable mutations</td>
<td>No targetable mutations</td>
<td>No targetable mutations</td>
</tr>
<tr>
<td>PD-L1 ≥50%</td>
<td>PD-L1 ≥50%</td>
<td>PD-L1 ≥50%</td>
<td>PD-L1 ≥50%</td>
<td>PD-L1 ≥50%</td>
<td>PD-L1 ≥50%</td>
</tr>
</tbody>
</table>

Non-squamous pathways

<table>
<thead>
<tr>
<th>RET fusion positive</th>
<th>NTRK fusion positive</th>
<th>KRAS G12C positive</th>
<th>METex14 skipping alteration</th>
<th>EGFRex20 insertion positive</th>
<th>BRAF V600 positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD-L1 &lt;50%</td>
<td>PD-L1 &lt;50%</td>
<td>PD-L1 &lt;50%</td>
<td>PD-L1 &lt;50%</td>
<td>PD-L1 &lt;50%</td>
<td>PD-L1 &lt;50%</td>
</tr>
<tr>
<td>No targetable mutations</td>
<td>No targetable mutations</td>
<td>No targetable mutations</td>
<td>No targetable mutations</td>
<td>No targetable mutations</td>
<td>No targetable mutations</td>
</tr>
<tr>
<td>PD-L1 ≥50%</td>
<td>PD-L1 ≥50%</td>
<td>PD-L1 ≥50%</td>
<td>PD-L1 ≥50%</td>
<td>PD-L1 ≥50%</td>
<td>PD-L1 ≥50%</td>
</tr>
</tbody>
</table>

PD-L1 <50% for squamous pathways, PD-L1 ≥50% for non-squamous pathways.
Base all treatment choices on **shared decision making**. Think about enrolment into a clinical trial as an option at each step.

**Platinum doublet chemotherapy**
- **Pembrolizumab** (if PD-L1 >1%) *(TA428)*
- **Atezolizumab** *(any PD-L1 0-100%)*(TA520)
- **Nivolumab** *(any PD-L1 0-100%)* *(TA655)*

**Pembrolizumab and carboplatin and paclitaxel** *(TA770)*
- **Atezolizumab** *(any PD-L1 0-100%)* *(TA520)*
- **Pembrolizumab** *(if PD-L1 >1%)* *(TA428)*
- **Nivolumab** *(any PD-L1 0-100%)* *(TA655)*
- **Docetaxel**

**PD-L1 <50%**

**Cancer Drugs Fund**
- **TA000**

**Disease progression**

**NHSE policy**

**No targetable mutations**

**July 2023**
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

- Pembrolizumab and carboplatin and paclitaxel (TA770) **Only if urgent clinical intervention is needed**
  - Docetaxel

- Pembrolizumab (TA531)
  - Platinum doublet chemotherapy
    - Docetaxel

- Atezolizumab (TA705)

**No targetable mutations**

- PD-L1 ≥50%

Cancer Drugs Fund

TA000

Disease progression

NHSE policy

NICE National Institute for Health and Care Excellence

Squamous No targetable mutations PD-L1 ≥50% July 2023
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

- **Platinum doublet chemotherapy**

  - Pembrolizumab (if PD-L1 >1%) (TA428)
  - Atezolizumab (any PD-L1 0-100%) (TA520)
  - Nivolumab (any PD-L1 0-100%) (TA655)

  - Docetaxel

  - Entrectinib (TA644)
  - Larotrectinib (TA630)

- **Pembrolizumab and carboplatin and paclitaxel (TA770)**

  - Docetaxel

  - Entrectinib (TA664)
  - Larotrectinib (TA630)

- **Docetaxel**

  - Entrectinib (TA644)
  - Larotrectinib (TA630)

NTRK fusion positive PD-L1 <50%

Squamous

Cancer Drugs Fund

Disease progression

NHSE policy
Base all treatment choices on **shared decision making**. Think about enrolment into a clinical trial as an option at each step.

- **Pembrolizumab and carboplatin and paclitaxel (TA770)**
  - *Only if urgent clinical intervention is needed*
  - **Docetaxel**
    - **Entrectinib (TA644)**
    - **Larotrectinib (TA630)**
  - ** platinum doublet chemotherapy**
    - **Docetaxel**
      - **Entrectinib (TA644)**
      - **Larotrectinib (TA630)**

- **Pembrolizumab (TA531)**
- **Atezolizumab (TA705)**

---

**NTRK fusion positive**

**PD-L1 ≥50%**

---

**Cancer Drugs Fund**

**TA000**

**Disease progression**

**NHSE policy**
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.
Base all treatment choices on **shared decision making**. Think about enrolment into a clinical trial as an option at each step.

**Pembrolizumab and carboplatin and paclitaxel (TA770)**

*Only if urgent clinical intervention is needed*

- Docetaxel
- Sotorasib (TA781)

**Pembrolizumab (TA531)**

**Atezolizumab (TA705)**

**Platinum doublet chemotherapy**

**Sotorasib (TA781)**

- Docetaxel
- Sotorasib (TA781)

**Docetaxel**

**Sotorasib (TA781)**

- Platinum doublet chemotherapy
- Docetaxel

**Cancer Drugs Fund**

**TA000**

**Disease progression**

**NHSE policy**

**Squamous**

**KRAS G12C positive**

**PD-L1 ≥50%**

**July 2023**
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

- **Pembrolizumab and carboplatin and paclitaxel (TA770)**
  - Only if urgent clinical intervention is needed
    - **Docetaxel**
    - **Tepotinib (TA789)**

- **Pembrolizumab (TA531)**
  - **Atezolizumab (TA705)**
    - **Platinum doublet chemotherapy**
      - **Tepotinib (TA789)**

- **Tepotinib (TA789)**
  - **Platinum doublet chemotherapy**
    - **Docetaxel**

- **Platinum doublet chemotherapy**
  - **Pembrolizumab (if PD-L1 >1%) (TA428)**
  - **Atezolizumab (any PD-L1 0-100%) (TA520)**
  - **Nivolumab (any PD-L1 0-100%) (TA655)**

- **Cancer Drugs Fund**
  - **TA000**
  - **Disease progression**
  - **NHSE policy**

- **July 2023**

- **PD-L1 ≥50%**

- **Squamous**
  - **METex14 skipping alteration**
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

- Pembrolizumab and carboplatin and paclitaxel (TA770)
  - Only if urgent clinical intervention is needed
    - Docetaxel (TA855)
    - Mobocertinib (TA855)

- Pembrolizumab (TA531)
  - Atezolizumab (TA705)
  - Platinum doublet chemotherapy
    - Docetaxel
    - Mobocertinib (TA855)
    - Mobocertinib (TA855)

Cancer Drugs Fund

- TA000
- Disease progression
- NHSE policy

EGFRex20 insertion positive
- PD-L1 ≥50%

Squamous

July 2023

National Institute for Health and Care Excellence
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

Platinum doublet chemotherapy

Pembrolizumab and carboplatin and paclitaxel (TA770)

Dabrafenib and trametinib (TA898)

Docetaxel

Platinum doublet chemotherapy

Atezolizumab (any PD-L1 0-100%) (TA520)

Pembrolizumab (if PD-L1 >1%) (TA428)

Nivolumab (any PD-L1 0-100%) (TA655)

Docetaxel

Docetaxel

Pembrolizumab (if PD-L1 >1%) (TA428)

Atezolizumab (any PD-L1 0-100%) (TA520)

Nivolumab (any PD-L1 0-100%) (TA655)

Docetaxel

Pembrolizumab (if PD-L1 >1%) (TA428)

Atezolizumab (any PD-L1 0-100%) (TA520)

Nivolumab (any PD-L1 0-100%) (TA655)

Docetaxel

Pembrolizumab (if PD-L1 >1%) (TA428)

Atezolizumab (any PD-L1 0-100%) (TA520)

Nivolumab (any PD-L1 0-100%) (TA655)

Platinum doublet chemotherapy

Cancer Drugs Fund

Disease progression

NHSE policy

July 2023

Squamous

BRAF V600 positive

PD-L1 <50%
Base all treatment choices on **shared decision making**. Think about enrolment into a clinical trial as an option at each step.

- **BRAF V600 positive**
  - **PD-L1 ≥50%**

  - **Squamous**
    - Atezolizumab (any PD-L1 0-100%) (TA520)
    - Pembrolizumab (if PD-L1 >1%) (TA428)
    - Nivolumab (any PD-L1 0-100%) (TA655)
    - Docetaxel

  - **Platinum doublet chemotherapy**

  - **Disease progression**

  - **NHSE policy**

  - **Cancer Drugs Fund**
    - TA000

- **Docetaxel**
  - Pembrolizumab (TA531)
  - Atezolizumab (TA705)

- **Dabrafenib and trametinib (TA898)**

  - **Platinum doublet chemotherapy**

- **Only if urgent clinical intervention is needed**
  - Pembrolizumab and carboplatin and paclitaxel (TA770)

  - **Docetaxel**

- **Nivolumab**
  - Pembrolizumab (if PD-L1 >1%) (TA428)
  - Atezolizumab (any PD-L1 0-100%) (TA520)
  - Nivolumab (any PD-L1 0-100%) (TA655)
  - Docetaxel

- **Pembrolizumab and carboplatin and paclitaxel (TA770)**
  - **Only if urgent clinical intervention is needed**

- **Docetaxel**
  - Pembrolizumab (if PD-L1 >1%) (TA428)
  - Atezolizumab (any PD-L1 0-100%) (TA520)
  - Nivolumab (any PD-L1 0-100%) (TA655)
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

- Pembrolizumab and pemetrexed and platinum chemotherapy (TA683)
  - Docetaxel
  - Docetaxel and nintedanib (TA347)
- Pembrolizumab (TA531) and Atezolizumab (TA705)
  - Platinum doublet chemotherapy
    - Pemetrexed and cisplatin (TA181)
    - Pemetrexed maintenance (TA190)
    - Pemetrexed and carboplatin
      - Pemetrexed maintenance (TA402)
        - Pemetrexed maintenance
          - Docetaxel
          - Docetaxel and nintedanib (TA347)

- No targetable mutations
  - PD-L1 ≥50%
  - Non-squamous
  - Pemetrexed maintenance (TA190)

Cancer Drugs Fund
- TA000
  - Disease progression
  - NHSE policy

July 2023
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

Cancer Drugs Fund

Disease progression

NHSE policy

TA000

PD-L1 <50%

RET fusion positive

July 2023

Non-squamous
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

- **Platinum doublet chemotherapy**
  - Pembrolizumab and pemetrexed and platinum chemotherapy (TA683)
  - Atezolizumab and bevacizumab, carboplatin and paclitaxel (TA584)

- **Atezolizumab**
  - Any PD-L1 0-100% (TA520)
  - Pembrolizumab if PD-L1 >1% (TA428)
  - Nivolumab if PD-L1 >1% (TA713)
  - Docetaxel and nintedanib (TA347)

- **Entrectinib** (TA644)
  - Larotrectinib (TA630)

- **Pemetrexed maintenance**
  - Pembrolizumab (if PD-L1 >1%) (TA428)
  - Atezolizumab (any PD-L1 0-100%) (TA520)
  - Nivolumab (if PD-L1 >1%) (TA713)
  - Docetaxel (TA347)

- **Pemetrexed and cisplatin (TA181)**
  - Pemetrexed maintenance (TA190)

- **Pemetrexed and carboplatin**
  - Pemetrexed maintenance (TA402)

- **Atezolizumab and bevacizumab, carboplatin and paclitaxel (TA584)**
  - Pemetrexed maintenance

- **Pembrolizumab and pemetrexed and platinum chemotherapy (TA683)**
  - Docetaxel
  - Docetaxel and nintedanib (TA347)

- **Entrectinib** (TA644)
  - Larotrectinib (TA630)

**Cancer Drugs Fund**
- TA000
- Disease progression
- NHSE policy

**July 2023**

**Non-squamous**

**NTRK fusion positive**

**PD-L1 <50%**
Base all treatment choices on **shared decision making**. Think about enrolment into a clinical trial as an option at each step.

Pembrolizumab and pemetrexed and platinum chemotherapy (TA683)

- **Docetaxel**
- **Entrectinib** (TA644)
- **Larotrectinib** (TA630)

Pembrolizumab (TA531)

- **Platinum doublet chemotherapy**

- **Pemetrexed and cisplatin (TA181)**

- **Pemetrexed and carboplatin**

Atezolizumab (TA705)

- **Pemetrexed and maintenance (TA190)**

- **Pemetrexed maintenance (TA402)**

Platinum doublet chemotherapy

- **Pemetrexed and maintenance (TA402)**

- **Pemetrexed maintenance**

Docetaxel and nintedanib (TA347)

- **Docetaxel**

- **Entrectinib** (TA644)

- **Larotrectinib** (TA630)

Cancer Drugs Fund

- **TA000**

- **Disease progression**

- **NHSE policy**

NTRK fusion positive

- **PD-L1 ≥50%**

July 2023

Non-squamous

NTRK fusion positive

PD-L1 ≥50%

July 2023
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

- **KRAS G12C positive**
  - PD-L1 <50%
    - Platinum doublet chemotherapy
    - Pembrolizumab and pemetrexed and platinum chemotherapy (TA683)
    - Atezolizumab and bevacizumab, carboplatin and paclitaxel (TA584)
    - Docetaxel and nintedanib (TA347)
    - Pembrolizumab and nintedanib and platinum chemotherapy (TA632)
    - Sotorasib (TA781)

- **KRAS G12C negative**
  - Pembrolizumab and pemetrexed and carboplatin (TA428)
  - Atezolizumab and bevacizumab, carboplatin and paclitaxel (TA584)
  - Docetaxel and nintedanib (TA347)
  - Pembrolizumab and nintedanib and platinum chemotherapy (TA632)
  - Sotorasib (TA781)

- **Pembrolizumab** (any PD-L1 0-100%)
  - Docetaxel (TA428)
  - Nivolumab (TA520)

- **Atezolizumab** (any PD-L1 0-100%)
  - Docetaxel (TA428)
  - Pembrolizumab (if PD-L1 >1%) (TA428)

- **Nivolumab** (if PD-L1 >1%)
  - Docetaxel (TA428)

- **Docetaxel**
  - Pembrolizumab (if PD-L1 0-100%)
  - Nivolumab (if PD-L1 >1%)

- **Pemetrexed** and cisplatin (TA181)
  - Docetaxel and nintedanib (TA347)
  - Docetaxel (TA347)

- **Pemetrexed** maintenance
  - Docetaxel and nintedanib (TA347)

- **Pemetrexed**
  - Docetaxel and nintedanib (TA347)

- **Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.**
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

**Mobocertinib** (TA855)

- **Platinum doublet chemotherapy**
  - *Mobocertinib (FFD-L1 >1%) (TA428)*
  - *Atezolizumab (any PD-L1 0-100%) (TA205)*
  - *Docetaxel and nintedanib (TA347)*
- **Pemetrexed and carboplatin**
  - *Docetaxel and nintedanib (TA347)*
  - *Mobocertinib (TA855)*
- **Pemetrexed and maintenance**
  - *Docetaxel and nintedanib (TA347)*
- **Pemetrexed maintenance**
  - *Docetaxel and nintedanib (TA347)*

**Docetaxel**

- *Docetaxel* and *nintedanib (TA347)*

**Pemetrexed and carboplatin**

- *Pemetrexed (TA186)*

**Docetaxel and nintedanib**

- *Docetaxel and nintedanib (TA347)*

**Atezolizumab**

- *Atezolizumab (any PD-L1 0-100%) (TA205)*

**Pembrolizumab**

- *Pembrolizumab (if PD-L1 >1%) (TA428)*

**Nivolumab**

- *Nivolumab (if PD-L1 >1%) (TA713)*

**Docetaxel and nintedanib**

- *Docetaxel and nintedanib (TA347)*

**Platinum doublet chemotherapy**

- *Docetaxel and nintedanib (TA347)*

**Pemetrexed and maintenance**

- *Docetaxel and nintedanib (TA347)*

**Docetaxel and nintedanib**

- *Docetaxel and nintedanib (TA347)*

**Mobocertinib**

- *Mobocertinib (TA855)*

**Pemetrexed and carboplatin**

- *Pemetrexed (TA186)*

**Pemetrexed maintenance**

- *Pemetrexed maintenance (TA402)*

**Docetaxel and nintedanib**

- *Docetaxel and nintedanib (TA347)*

**Atezolizumab**

- *Atezolizumab (any PD-L1 0-100%) (TA205)*

**Pembrolizumab**

- *Pembrolizumab (if PD-L1 >1%) (TA428)*

**Nivolumab**

- *Nivolumab (if PD-L1 >1%) (TA713)*

**Docetaxel**

- *Docetaxel* and *nintedanib (TA347)*

**Pemetrexed and carboplatin**

- *Pemetrexed and carboplatin (TA428)*

**Pemetrexed maintenance**

- *Pemetrexed maintenance (TA402)*

**Docetaxel and nintedanib**

- *Docetaxel and nintedanib (TA347)*

**Platinum doublet chemotherapy**

- *Docetaxel and nintedanib (TA347)*

**Pemetrexed and maintenance**

- *Docetaxel and nintedanib (TA347)*

**Docetaxel and nintedanib**

- *Docetaxel and nintedanib (TA347)*

**Mobocertinib**

- *Mobocertinib (TA855)*

**Pemetrexed and maintenance**

- *Pemetrexed maintenance (TA402)*

**Docetaxel and nintedanib**

- *Docetaxel and nintedanib (TA347)*

**Atezolizumab**

- *Atezolizumab (any PD-L1 0-100%) (TA205)*

**Pembrolizumab**

- *Pembrolizumab (if PD-L1 >1%) (TA428)*

**Nivolumab**

- *Nivolumab (if PD-L1 >1%) (TA713)*

**Docetaxel**

- *Docetaxel* and *nintedanib (TA347)*

**Pemetrexed and maintenance**

- *Pemetrexed and maintenance (TA402)*

**Docetaxel and nintedanib**

- *Docetaxel and nintedanib (TA347)*

**Mobocertinib**

- *Mobocertinib (TA855)*

**Pemetrexed and carboplatin**

- *Pemetrexed and carboplatin (TA428)*

**Pemetrexed maintenance**

- *Pemetrexed maintenance (TA402)*
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

Pembrolizumab (TA531)  Atezolizumab (TA705)

Platinum doublet chemotherapy  Pemetrexed and cisplatin (TA181)  Pemetrexed and carboplatin

Pemetrexed maintenance (TA190)  Pemetrexed maintenance (TA402)  Pemetrexed maintenance

Docetaxel and nintedanib (TA347)  Docetaxel  Mobocertinib (TA855)

Mobocertinib (TA855)  Docetaxel  Docetaxel and nintedanib (TA347)
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

- **BRAF V600 positive**
  - **PD-L1 <50%**
    - Docetaxel
    - Docetaxel and nintedanib (TA347)
  - **PD-L1 ≥50%**
    - Pembrolizumab and pembrolizumab and platinum chemotherapy (TA683)
    - Atezolizumab and bevacizumab, carboplatin and paclitaxel (TA584)
    - Pembrolizumab and pembrolizumab and carboplatin (TA348)
    - Pembrolizumab and pembrolizumab and cisplatin (TA181)
    - Platinum doublet chemotherapy
    - Docetaxel
    - Docetaxel and nintedanib (TA347)

- **BRAF V600 negative**
  - **PD-L1 <50%**
    - Pembrolizumab (any PD-L1 0-100%) (TA520)
    - Pembrolizumab (if PD-L1 >1%) (TA428)
    - Nivolumab (if PD-L1 >1%) (TA713)
    - Docetaxel and nintedanib (TA347)
    - Docetaxel
  - **PD-L1 ≥50%**
    - Pembrolizumab and pembrolizumab and carboplatin (TA348)
    - Pembrolizumab and pembrolizumab and cisplatin (TA181)
    - Platinum doublet chemotherapy
    - Docetaxel
    - Docetaxel and nintedanib (TA347)

- **Non-squamous**
  - **PD-L1 <50%**
    - Pembrolizumab and pembrolizumab and carboplatin (TA348)
    - Pembrolizumab and pembrolizumab and cisplatin (TA181)
    - Platinum doublet chemotherapy
    - Docetaxel
    - Docetaxel and nintedanib (TA347)
  - **PD-L1 ≥50%**
    - Pembrolizumab and pembrolizumab and carboplatin (TA348)
    - Pembrolizumab and pembrolizumab and cisplatin (TA181)
    - Platinum doublet chemotherapy
    - Docetaxel
    - Docetaxel and nintedanib (TA347)
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

Cancer Drugs Fund

Disease progression

NHSE policy

TA000

BRAF V600 positive

PD-L1 ≥50%

July 2023

Non-squamous

Pembrolizumab (TA531)

Atezolizumab (TA705)

Pembrolizumab and pemetrexed and platinum chemotherapy (TA683)

Docetaxel

Docetaxel and nintedanib (TA347)

Pemetrexed and carboplatin (TA402)

Pemetrexed maintenance (TA496)

Platinum doublet chemotherapy

Pemetrexed and carboplatin (TA818)

Pemetrexed maintenance (TA462)

Pemetrexed and cisplatin (TA181)

Pemetrexed maintenance

Pemetrexed and cisplatin (TA181)

Platinum doublet chemotherapy

Pemetrexed and carboplatin (TA818)

Pemetrexed maintenance (TA496)

Pemetrexed maintenance

Atezolizumab and bevacizumab, carboplatin and paclitaxel (TA584)

Docetaxel

Docetaxel and nintedanib (TA347)

Pemetrexed and carboplatin (TA402)

Pemetrexed maintenance (TA496)

Pemetrexed maintenance

Pemetrexed and cisplatin (TA181)

Pemetrexed maintenance

Pemetrexed maintenance

Pemetrexed and cisplatin (TA181)

Pemetrexed maintenance

Pemetrexed maintenance

Atezolizumab (any PD-L1 0-100%) (TA520)

Pembrolizumab (if PD-L1 >1%) (TA428)

Nivolumab (if PD-L1 >1%) (TA713)

Docetaxel

Docetaxel and nintedanib (TA347)

Pemetrexed and cisplatin (TA181)

Docetaxel

Docetaxel and nintedanib (TA347)

Pemetrexed and cisplatin (TA181)

Pemetrexed maintenance (TA496)

Pemetrexed maintenance

Atezolizumab (any PD-L1 0-100%) (TA520)

Nivolumab (if PD-L1 >1%) (TA713)

Docetaxel

Docetaxel and nintedanib (TA347)

Pemetrexed and cisplatin (TA181)

Docetaxel

Docetaxel and nintedanib (TA347)

Pemetrexed and cisplatin (TA181)

Pemetrexed maintenance (TA496)

Pemetrexed maintenance

Atezolizumab (any PD-L1 0-100%) (TA520)

Nivolumab (if PD-L1 >1%) (TA713)

Docetaxel

Docetaxel and nintedanib (TA347)

Platinum doublet chemotherapy

Pemetrexed and carboplatin (TA818)

Pemetrexed maintenance (TA496)

Pemetrexed maintenance

Pemetrexed maintenance

Pemetrexed and cisplatin (TA181)

Pemetrexed maintenance

Pemetrexed maintenance

Pemetrexed maintenance

Atezolizumab (any PD-L1 0-100%) (TA520)

Nivolumab (if PD-L1 >1%) (TA713)

Docetaxel

Docetaxel and nintedanib (TA347)

Platinum doublet chemotherapy

Pemetrexed and carboplatin (TA818)

Pemetrexed maintenance (TA496)

Pemetrexed maintenance

Pemetrexed maintenance

Pemetrexed maintenance

Atezolizumab (any PD-L1 0-100%) (TA520)

Nivolumab (if PD-L1 >1%) (TA713)

Docetaxel

Docetaxel and nintedanib (TA347)

Platinum doublet chemotherapy

Pemetrexed and carboplatin (TA818)

Pemetrexed maintenance (TA496)

Pemetrexed maintenance

Pemetrexed maintenance

Pemetrexed maintenance

Atezolizumab (any PD-L1 0-100%) (TA520)

Nivolumab (if PD-L1 >1%) (TA713)

Docetaxel

Docetaxel and nintedanib (TA347)

Platinum doublet chemotherapy

Pemetrexed and carboplatin (TA818)

Pemetrexed maintenance (TA496)

Pemetrexed maintenance

Pemetrexed maintenance

Pemetrexed maintenance

Atezolizumab (any PD-L1 0-100%) (TA520)

Nivolumab (if PD-L1 >1%) (TA713)

Docetaxel

Docetaxel and nintedanib (TA347)

Platinum doublet chemotherapy

Pemetrexed and carboplatin (TA818)

Pemetrexed maintenance (TA496)

Pemetrexed maintenance

Pemetrexed maintenance

Pemetrexed maintenance

Atezolizumab (any PD-L1 0-100%) (TA520)

Nivolumab (if PD-L1 >1%) (TA713)

Docetaxel

Docetaxel and nintedanib (TA347)

Platinum doublet chemotherapy

Pemetrexed and carboplatin (TA818)

Pemetrexed maintenance (TA496)

Pemetrexed maintenance

Pemetrexed maintenance

Pemetrexed maintenance

Atezolizumab (any PD-L1 0-100%) (TA520)

Nivolumab (if PD-L1 >1%) (TA713)

Docetaxel

Docetaxel and nintedanib (TA347)

Platinum doublet chemotherapy

Pemetrexed and carboplatin (TA818)

Pemetrexed maintenance (TA496)

Pemetrexed maintenance

Pemetrexed maintenance

Pemetrexed maintenance

Atezolizumab (any PD-L1 0-100%) (TA520)

Nivolumab (if PD-L1 >1%) (TA713)

Docetaxel

Docetaxel and nintedanib (TA347)
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

- **Crizotinib** (TA529)
- **Entrectinib** (TA643)

- **Platinum doublet chemotherapy**
  - **Pemetrexed and cisplatin** (TA181)
  - **Pemetrexed and carboplatin**
    - **Pemetrexed maintenance** (TA190)
    - **Pemetrexed maintenance** (TA402)
    - **Pemetrexed maintenance**

- **Atezolizumab and bevacizumab, carboplatin and paclitaxel** (TA584)

- **Docetaxel and nintedanib** (TA347)

- **Entrectinib** (TA643)

- **Crizotinib** (TA529)

- **ROS-1 positive**

- **Pemetrexed and cisplatin** (TA190)

- **Pemetrexed maintenance (TA402)**

- **Pemetrexed and carboplatin**

- **Atezolizumab and bevacizumab, carboplatin and paclitaxel (TA584)**

- **Docetaxel**

- **Docetaxel and nintedanib (TA347)**

- **Platinum doublet chemotherapy**

- **Pemetrexed and cisplatin (TA181)**

- **Pemetrexed and carboplatin**

- **Atezolizumab and bevacizumab, carboplatin and paclitaxel (TA584)**

- **Docetaxel**

- **Docetaxel and nintedanib (TA347)**

- **Pembrolizumab (if PD-L1 >1%)** (TA428)

- **Atezolizumab (any PD-L1 0-100%)** (TA520)

- **Nivolumab (if PD-L1 >1%)** (TA713)

- **Docetaxel**

- **Docetaxel and nintedanib (TA347)**

- **Pemetrexed and cisplatin (TA181)**

- **Pemetrexed maintenance (TA402)**

- **Pemetrexed maintenance**

- **Pemetrexed maintenance**

- **Pemetrexed maintenance**

- **Docetaxel**

- **Docetaxel and nintedanib (TA347)**

- **Pemetrexed and cisplatin (TA181)**

- **Pemetrexed maintenance (TA402)**

- **Pemetrexed maintenance**

- **Pemetrexed maintenance**

- **Docetaxel**

- **Docetaxel and nintedanib (TA347)**

- **Pemetrexed and cisplatin (TA181)**

- **Pemetrexed maintenance (TA402)**

- **Pemetrexed maintenance**

- **Pemetrexed maintenance**

- **Docetaxel**

- **Docetaxel and nintedanib (TA347)**

- **Pemetrexed and cisplatin (TA181)**

- **Pemetrexed maintenance (TA402)**

- **Pemetrexed maintenance**

- **Pemetrexed maintenance**

- **Docetaxel**

- **Docetaxel and nintedanib (TA347)**

- **Pemetrexed and cisplatin (TA181)**

- **Pemetrexed maintenance (TA402)**

- **Pemetrexed maintenance**

- **Pemetrexed maintenance**

- **Docetaxel**

- **Docetaxel and nintedanib (TA347)**
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.

**Osimertinib (TA654)**

**Afatinib (TA310)**

**Dacomitinib (TA595)**

**Erlotinib (TA258)**

**Gefitinib (TA192)**

**T790M positive?**

**YES**

**NO**

**Docetaxel and nintedanib (TA347)**

**Atezolizumab (any PD-L1 0-100%) (TA520)**

**Pembrolizumab (if PD-L1 >1%) (TA428)**

**Nivolumab (if PD-L1 >1%) (TA713)**

**Docetaxel and nintedanib (TA347)**

**Pemetrexed (TA402)**

**Platinum doublet chemotherapy**

**Pemetrexed and carboplatin (TA190)**

**Pemetrexed and cisplatin (TA181)**

**Pemetrexed maintenance (TA676)**

**Platinum doublet chemotherapy**

**Docetaxel and nintedanib (TA347)**

**Docetaxel**

**Platinum doublet chemotherapy**

**Pemetrexed and carboplatin**

**Pemetrexed**

**Pemetrexed maintenance (TA676)**

**Docetaxel**

**Pemetrexed and cisplatin (TA181)**

**Pemetrexed maintenance (TA676)**

**Docetaxel and nintedanib (TA347)**

**Docetaxel and nintedanib (TA347)**

**Docetaxel and nintedanib (TA347)**

**Docetaxel and nintedanib (TA347)**

**Docetaxel and nintedanib (TA347)**
Base all treatment choices on shared decision making. Think about enrolment into a clinical trial as an option at each step.